

## COVID-19 and bioethics - Part 3 2 days webinar

### Pandemic and research ethics: democracy, placebo and post-trial access

June 4 (Fri), 11 (Fri), 2021 9:00-11:30am (Brazil); 9:00-11:30pm (Japan);  
8:00-10:30am (NY, US); 2:00-4:30pm (CET/Johannesburg)

- ◇ After official webinar, the web meeting room will be open 30 min for free talk.
- ◇ Webinar is provided by Zoom and recorded for publication. The remarks of participants will be publicized only if individually permitted.

#### Registration details

Language: English    Registration Free

Co-organized by COVID-19 Task Force, Japan Association for Bioethics & Brazilian Society of Bioethics

Supported by the Japanese Association of Pharmaceutical Medicine (JAPhMed) and the International Federation of Associations of Pharmaceutical Physicians and Pharmaceutical Medicine (IFAPP)

Cooperation: Clinical Evaluation; Bioethics Policy Study Group; Pharmaceutical Study Group

Supported by Clinical Research Risk Management Study Group    Inquiry: Chieko Kurihara, COVID-19 Task Force  
chieko.kurihara@nifty.ne.jp

#### Moderators:

Takeo Saio, COVID-19 Task Force, Japan Association for Bioethics  
Kyoko Imamura, IFAPP/JAPhMed

#### Lecturers (25 min talk and discussion for each):

- June 4**
1. Chieko Kurihara, et al. : Opening remarks and situation in Japan
  2. Ruth Macklin: Overview on placebo, post-trial, international covenants, considering COVID-19 situation
  3. Peter Lurie: Revisiting the Debate over Placebo Use in Developing Countries in the Age of COVID-19
  4. Ulf Schmidt: From Nuremberg to Helsinki: Historicising Research Ethics during Health crisis
- June 11**
5. Ames Dhai: Ethics in vaccine allocation in developing countries
  6. Tammam Aloudat: Médecins Sans Frontières (MSF) Access Campaign for equitable access in the world
  7. Dirceu Greco: Post-trial access for all
  8. Francis P. Crawley: special comments
  9. Free discussion

In the 1990s HIV/AIDS pandemic raised substantial discussion of research ethics, mainly long-lasting debate on placebo-controlled clinical trial and post-trial access to established intervention. At the year of 2019, some argued that this debate is outdated and we should drive ourselves forward to new trend of research ethics. Just at this occasion, COVID-19 pandemic happened.

In this web-based workshop we will debate on the following topics:

- What is the international agreed ethical standard on placebo-controlled clinical trial and post-trial access considering COVID-19 situation?
- What is the ethical principle to provide established intervention to those who need it, considering egalitarian principles of priority setting of resource allocation?
- Does the background situation of the maturity of democracy and International human rights covenants play critical role for ethical research in and after COVID-19 situation?

We invite speakers who took historically critical roles on the above questions, expecting presentations considering local and global situations.